


Nifty Outlook

Markets traded under pressure for the fifth consecutive session and lost nearly a percent. It opened weak following feeble global cues and further drifted lower as the session progressed. Though it tried to recoup some of its losses in the second half but failed to make any decisive move. Consequently, the Nifty index ended lower by 1.1% at 13,817.55 levels. On the sector front, a mixed trend was witnessed as IT, Auto and Realty were the top losers whereas Consumer Durables, Oil & Gas and Banks ended in the green. Amid all, the broader indices outperformed the benchmark as both Midcap and Smallcap restricted the losses to 0.5% each.

Markets may see a breather on Friday after the recent slide but volatility would remain high. Nifty respected the support zone at 13,700 but sustainability above the same is critical for a decisive rebound. Considering the prevailing scenario and upcoming event i.e. Union Budget, we suggest continuing with hedged positions and preferring index majors over others.



	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	13850	14500	13000

News

- **Tata Power Solar** has received a Letter of Award to build 95 MW of ground mounted Solar PV project for GSECL. The order value of the project is approximately Rs. 460 cr. The Commercial operation date for this project is set for April 2022.
- **DB Corp** announced its numbers wherein revenue was down 17.4% YoY to Rs. 494 cr. Its net profit rose by 21.3% YoY to Rs. 99 cr as against Rs. 81.6 cr.
- **Colgate Palmolive** announced its Q3FY21 numbers wherein consolidated revenue was up 7.4% YoY to Rs. 1,232 cr Its EBITDA grew by 17.3% YoY to Rs. 371 cr. Its consolidated net profit was up 24.7% to Rs. 248 cr.

Religare Super Idea**

Scrip	Buy/Sell	CMP	Initiation Range	SL*	Target
DLF	BUY	261	258-260	252	275

**Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

*Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.

Derivative Ideas **					
Instrument	B/S	Lot	INITIATION RANGE	SL	TARGET
HAVELLS	BUY	CASH	1150-1160	1120	1230

Sectors to watch	
Sector Name	Outlook
IT	BULLISH
BANKS	STABLE
FMCG	BULLISH

FII & DII Cash Segment (Rs. in Cr.)			
Category	Amt.	MTD	FYTD
FII**	-765	20312	169408
DII**	-387	-16147	-125619

Trade Stats		
	NO OF CONTRACTS	TURNOVER IN CR
IDXFUTS	724858	64637
IDXOPT	86590598	18354
STKFUTS	1755194	140473

**Provisional data as on 27th January, 2021

Derivative Ideas

HAVELLS FEB FUT added around 23% in open interest addition as LONG buildup was seen in it in till closing time. Current chart pattern also indicates further up move in its price. We suggest buying HAVELLS as per below levels.

Strategy:- BUY HAVELLS BETWEEN 1150-1160 SL 1120 TARGET 1230.

Investment Pick - SBI Life Insurance Company Ltd.

Scrip	CMP	Recommendation Price	Target	Duration
SBI Life Insurance Company Ltd.	872.55	874	1,069	9-12 Months

- SBI Life Insurance Company Ltd. is a joint venture between State Bank of India and BNP Paribas Cardiff S.A. It is one of the leading life insurers in India with a healthy market share of 13.3% in terms of Individual rated premium. SBI Life offers a comprehensive range of life insurance and pension products at competitive prices, ensuring high standards of customer service and world-class operating efficiency.
- Within the industry, SBI Life is one of our preferred picks given its huge untapped client base, wide distribution reach and industry-leading cost ratios. Further, increased focus on business through digital channels and a strong distribution platform should lead to consistent market share gains for the company. We initiate with a Buy rating on the stock with a target price of Rs. 1069.

CACT Calendar - January 2021 (Cash Dividend)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
24	25	26	27	28	29	30
			<ul style="list-style-type: none"> Dcm Shriram Limited Gail (India) Ltd. India Grid Trust Siemens Ltd. 	<ul style="list-style-type: none"> Gmm Pfaudler Ltd. Havells India Ltd. Indian Energy Exchange Ltd 	<ul style="list-style-type: none"> Srf Ltd. Zensar Technologies Ltd. 	

Result Calendar - January 2021

Mon	Tue	Wed	Thu	Fri	Sat
25 <ul style="list-style-type: none"> Aarti Drugs Ltd. Ap Apollo Tubes Ltd. Icici Securities Ltd Kotak Mahindra Bank Ltd. Larsen & Toubro Ltd. Navin Fluorine International Limited Uco Bank 	26	27 <ul style="list-style-type: none"> Axis Bank Ltd. Bank Of Baroda Canara Bank Emami Ltd. Hindustan Unilever Ltd. Icici Prudential Life Insurance Company Ltd India Cements Ltd. Marico Ltd. Nippon Life India Asset Management Ltd Tata Coffee Ltd. Welspun India Ltd. 	28 <ul style="list-style-type: none"> Aarti Industries Ltd. Alembic Ltd. Angel Broking Ltd Au Small Finance Bank Ltd Bharat Electronics Ltd. Blue Dart Express Ltd. Colgate-Palmolive (India) Ltd. Cummins India Ltd. Granules India Ltd. Ifb Industries Ltd. Interglobe Aviation Ltd Indian Railway Catering And Tourism Corporation Ltd Kei Industries Ltd. Kpit Technologies Ltd 	29 <ul style="list-style-type: none"> Adf Foods Ltd. Atul Ltd. Blue Star Ltd. Cipla Ltd. Dabur India Ltd. Dr.Reddy'S Laboratories Ltd. Exide Industries Ltd. Jk Lakshmi Cement Ltd. Kaya Ltd Dr. Lal Pathlabs Ltd Paushak Ltd. Subros Ltd. Upl Limited Uti Asset Management Company Ltd 	30 <ul style="list-style-type: none"> Amber Enterprises India Ltd Bcpl Railway Infra-structure Ltd Icici Bank Ltd. Relaxo Footwears Ltd. Shree Cement Ltd.

For complete schedule of more Company Results Calendar [click here](#).

CACT Calendar - January 2021 (E.G.M.)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
24	25	26	27	28	29	30
				<ul style="list-style-type: none"> Shree Rama Multi-Tech Ltd. 		

CACT Calendar - January 2021 (Buy Back of Shares)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
24	25	26	27	28	29	30
			<ul style="list-style-type: none"> Gail (India) Ltd. 			

CACT Calendar - January 2021 (Right Issue of Equity Shares)

Sun	Mon	Tue	Wed	Thu	Fri	Sat
24	25	26	27	28	29	30
			<ul style="list-style-type: none"> Emerald Leasing Finance & Investment Company Ltd 			

Religare Investment Calls

Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	CMP	Expected returns from CMP %
Cummins India	31-Jan-2020	Buy	Investment Call	585	705	20.5%	637	10.7%
Godrej Agrovet	13-Feb-2020	Buy	Investment Call	559	618	10.5%	530	16.5%
INOX Leisure	20-Aug-2020	Buy	High Conviction Ideas	282	376	33.3%	321	17.2%
Godrej Consumer Products	16-Sept-2020	Hold	Investment Call	706	845	19.7%	778	8.6%
Britannia Industries	22-Oct-2020	Buy	High Conviction Ideas	3,397	4,265	25.5%	3,604	18.3%
Castrol India	02-Nov-2020	Buy	Investment Call	114	151	32.5%	126	19.9%
Bharti Airtel	09-Nov-2020	Buy	High Conviction Ideas/ Diwali Picks	450	709	57.6%	571	24.2%
Nippon Life India Asset Management	09-Nov-2020	Hold	Diwali Picks	285	348	22.1%	318	9.4%
Sudarshan Chemical Industries	09-Nov-2020	Buy	Diwali Picks	442	583	31.9%	491	18.6%

*Current rating is based on returns potential

Buy - Potential Returns $\geq 10\%$ over 12 months

Hold - Potential Returns $\leq 10\%$ over 12 months

For Religare Investment calls performance [click here](#)

Religare Investment Calls

Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	CMP	Expected returns from CMP %
ITC	19-Nov-2020	Buy	Investment Call	190	238	25.3%	207	15.2%
Dabur India	24-Nov-2020	Buy	High Conviction Ideas	509	616	21.0%	528	16.7%
Axis Bank	28-Dec-2020	Hold	New Year Picks 2021	610	721	18.2%	671	7.5%
Coromandel International	28-Dec-2020	Buy	New Year Picks 2021	802	978	21.9%	828	18.1%
IRCTC	28-Dec-2020	Buy	New Year Picks 2021	1,409	1,755	24.6%	1,457	20.4%
JK Lakshmi Cement	28-Dec-2020	Buy	New Year Picks 2021	337	428	27.0%	319	34.2%
Mahindra and Mahindra	28-Dec-2020	Buy	New Year Picks 2021	711	889	25.0%	765	16.2%
Manappuram Finance	28-Dec-2020	Buy	New Year Picks 2021	164	205	25.0%	153	33.7%
Natco Pharma	28-Dec-2020	Buy	New Year Picks 2021	932	1,135	21.8%	894	26.9%
SBI Life Insurance	28-Dec-2020	Buy	New Year Picks 2021	874	1,069	22.3%	873	22.5%

*Current rating is based on returns potential

Buy - Potential Returns $\geq 10\%$ over 12 months

Hold - Potential Returns $\leq 10\%$ over 12 months

For Religare Investment calls performance [click here](#)

Research Product Basket

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

For cash market trading					For 1L margin*	
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call
Intraday Calls	Intraday	2 - 3	< 1 day	25%	25,000	8,000
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%	30,000	4,000
Master Pick	Weekly	1	1 month	15%	15,000	5,000
Religare Alpha	Opportunity	NA	2 - 3 months	20%	20,000	As per weightage
Cash		NA		10%	10,000	
Intraday Calls	These calls are flashed live on Ms Lync and ODIN with the purpose of squaring off positions on the same day. As a policy, we restrict our intraday cash market calls to less than 4 calls a day. Hence, funds should be allocated accordingly to have provision to trade in all calls.					
Live / RMD Calls	2 super ideas are flashed in RMD daily with a view of 3-4 days. Additionally as per market opportunity, we flash live calls during the day (including BTST calls). 3-4 such calls are made on a daily basis which might be open for 3-4 days. Funds should be allocated keeping in mind that there will be 7-8 such open calls daily.					
Master Pick	This is our weekly recommendation shortlisted on the basis of techno-funda analysis. 15% of funds is recommended to be allocated for Master Pick considering that there will be 3 open calls. The average open duration for this call will be 1 month.					
Religare Alpha	This is a portfolio of 8-10 stocks which are held with a view of 2-3 months. It is recommended to allocate 20% of funds for building this portfolio which will provide stability to the overall trading portfolio.					
Cash	10% surplus cash in the portfolio should be kept for the purposes of allocating it to opportunities as and when they arrive.					

For derivative market trading					For 1L margin*	
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call
Derivative Ideas	Daily	1 - 2	1 - 3 days	40%	40,000	40,000
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000
Cash		NA		10%	10,000	
Derivative Ideas	1 derivative idea is shared in RMD daily. It can be a plain vanilla F&O buy/sell call or an option strategy. Funds should be allocated assuming 2 such calls will be open at any time. These calls are open for 3-4 days on an average.					
Live Calls	These calls are flashed on MS Lync and ODIN during live market hours. These calls can be intraday or with a view of 2-3 days. Funds should be allocated considering 2 such calls will be open at any time. 3/4 times, these calls will be on Nifty / Bank Nifty only.					
Cash	It is recommended to hold 10% cash to capitalize on any opportunity that may arise in markets.					

Research Analysts

Ajit Mishra	ajit.mishra@religare.com
Himanshu Sharma	himanshu.sharma1@religare.com
Manoj M Vayalar	manoj.vayalar@religare.com
Nirvi Ashar	nirvi.ashar@religare.com
Rohit Khatri	rohit.khatri@religare.com
Suhanee Shome	suhanee.shome@religare.com

Before you use this research report , please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link : <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest , compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below , are given separately]

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No

	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No

	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest (if answer to F (a) above is Yes :

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above , are given below]

SS.No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results"